Evotec SE (EVT) - Total Assets

Latest as of March 2026: €1.64 Billion EUR ≈ $1.92 Billion USD

Based on the latest financial reports, Evotec SE (EVT) holds total assets worth €1.64 Billion EUR (≈ $1.92 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Evotec SE total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Evotec SE - Total Assets Trend (2001–2025)

This chart illustrates how Evotec SE's total assets have evolved over time, based on quarterly financial data. Explore Evotec SE long-term investment allocation to see how much of total assets are deployed in long-term investments.

Evotec SE - Asset Composition Analysis

Current Asset Composition (December 2025)

Evotec SE's total assets of €1.64 Billion consist of 42.9% current assets and 57.1% non-current assets.

Asset Category	Amount (EUR)	% of Total Assets
Cash & Equivalents	€418.52 Million	23.5%
Accounts Receivable	€213.51 Million	12.0%
Inventory	€29.32 Million	1.7%
Property, Plant & Equipment	€554.63 Million	31.2%
Intangible Assets	€31.57 Million	1.8%
Goodwill	€272.37 Million	15.3%

Asset Composition Trend (2001–2025)

This chart illustrates how Evotec SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Evotec SE (EVT) total market value.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Evotec SE's current assets represent 42.9% of total assets in 2025, an increase from 0.0% in 2001.
Cash Position: Cash and equivalents constituted 23.5% of total assets in 2025, up from 0.0% in 2001.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 0.0% in 2001.
Asset Diversification: The largest asset category is property, plant & equipment at 31.2% of total assets.

Evotec SE Competitors by Total Assets

Key competitors of Evotec SE based on total assets are shown below.

Company	Country	Total Assets
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	China	CN¥14.18 Billion
SIMCERE PHARMAC. GRP LTD F:S2P	Germany	€14.73 Billion
Curaleaf Holdings Inc. TO:CURA	Canada	CA$2.88 Billion
Beijing New Oriental Star Petrochemical Engineering Co Ltd SHE:002755	China	CN¥4.44 Billion
Walvax BioTech SHE:300142	China	CN¥11.13 Billion
Shanghai Yizhong Pharmaceutical Co Ltd SHG:688091	China	CN¥1.54 Billion
Cronos Group Inc TO:CRON	Canada	CA$1.18 Billion
Renhe Pharmacy Co Ltd SHE:000650	China	CN¥7.93 Billion

Evotec SE - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.68	2.03	2.84
Quick Ratio	1.60	1.93	2.78
Cash Ratio	0.00	0.80	0.00
Working Capital	€287.90 Million	€366.96 Million	€440.80 Million

Evotec SE - Advanced Valuation Insights

This section examines the relationship between Evotec SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	1.25
Latest Market Cap to Assets Ratio	0.47
Asset Growth Rate (YoY)	-7.0%
Total Assets	€1.78 Billion
Market Capitalization	$843.57 Million USD

Valuation Analysis

Below Book Valuation: The market values Evotec SE's assets below their book value (0.47x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Evotec SE's assets decreased by 7.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Evotec SE (2001–2025)

The table below shows the annual total assets of Evotec SE from 2001 to 2025.

Year	Total Assets	Change
2025-12-31	€1.78 Billion ≈ $2.08 Billion	-6.99%
2024-12-31	€1.91 Billion ≈ $2.24 Billion	-15.09%
2023-12-31	€2.25 Billion ≈ $2.63 Billion	-0.21%
2022-12-31	€2.26 Billion ≈ $2.64 Billion	+0.99%
2021-12-31	€2.24 Billion ≈ $2.61 Billion	+52.79%
2020-12-31	€1.46 Billion ≈ $1.71 Billion	+23.88%
2019-12-31	€1.18 Billion ≈ $1.38 Billion	+52.99%
2018-12-31	€771.88 Million ≈ $902.41 Million	+15.68%
2017-12-31	€667.27 Million ≈ $780.11 Million	+89.91%
2016-12-31	€351.37 Million ≈ $410.78 Million	+21.77%
2015-12-31	€288.54 Million ≈ $337.33 Million	+28.47%
2014-12-31	€224.60 Million ≈ $262.58 Million	-1.22%
2013-12-31	€227.38 Million ≈ $265.83 Million	+0.87%
2012-12-31	€225.43 Million ≈ $263.55 Million	+3.31%
2011-12-31	€218.21 Million ≈ $255.11 Million	+13.74%
2010-12-31	€191.86 Million ≈ $224.30 Million	+30.87%
2009-12-31	€146.60 Million ≈ $171.39 Million	-19.85%
2008-12-31	€182.90 Million ≈ $213.83 Million	-12.02%
2007-12-31	€207.88 Million ≈ $243.03 Million	+1.14%
2006-12-31	€205.53 Million ≈ $240.28 Million	+10.43%
2005-12-31	€186.11 Million ≈ $217.58 Million	+162.46%
2004-12-31	€70.91 Million ≈ $82.90 Million	+69.94%
2003-12-31	€41.73 Million ≈ $48.78 Million	+123.10%
2002-12-31	€18.70 Million ≈ $21.87 Million	-48.34%
2001-12-31	€36.20 Million ≈ $42.33 Million	--

About Evotec SE

XETRA:EVT Germany Drug Manufacturers - Specialty & Generic

Market Cap

$942.21 Million

€805.92 Million EUR

Market Cap Rank

#9819 Global

#1191 in Germany

Share Price

€4.54

Change (1 day)

-4.06%

52-Week Range

€4.12 - €7.46

All Time High

€45.35